Nektar Therapeutics (NASDAQ: NKTR) kicked off on Friday, up 23.76% from the previous trading day, before settling in for the closing price of $0.50. Over the past 52 weeks, NKTR has traded in a range of $0.43-$1.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -0.50% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -8.50%. With a float of $179.37 million, this company’s outstanding shares have now reached $185.78 million.
In an organization with 61 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 68.82%, operating margin of -92.39%, and the pretax margin is -121.1%.
Nektar Therapeutics (NKTR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 3.62%, while institutional ownership is 69.42%. The most recent insider transaction that took place on Feb 19 ’25, was worth 10,403. In this transaction Chief R&D Officer of this company sold 10,300 shares at a rate of $1.01, taking the stock ownership to the 316,604 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Legal Officer sold 11,040 for $1.01, making the entire transaction worth $11,150. This insider now owns 324,292 shares in total.
Nektar Therapeutics (NKTR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.04% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Take a look at Nektar Therapeutics’s (NKTR) current performance indicators. Last quarter, stock had a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.58, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.75 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Let’s dig in a bit further. During the last 5-days, its volume was 4.05 million. That was better than the volume of 2.3 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 39.11%. Additionally, its Average True Range was 0.08.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 22.89%, which indicates a significant decrease from 40.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 124.69% in the past 14 days, which was higher than the 89.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7835, while its 200-day Moving Average is $1.0868. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $0.6692. Second resistance stands at $0.7206. The third major resistance level sits at $0.7913. If the price goes on to break the first support level at $0.5471, it is likely to go to the next support level at $0.4764. The third support level lies at $0.4250 if the price breaches the second support level.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
The company with the Market Capitalisation of 114.95 million has total of 186,104K Shares Outstanding. Its annual sales at the moment are 98,430 K in contrast with the sum of -118,960 K annual income. Company’s last quarter sales were recorded 29,180 K and last quarter income was 7,260 K.
